At the time of writing, AbCellera Biologics Inc [ABCL] stock is trading at $5.15, up 14.96%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABCL shares have gain 21.46% over the last week, with a monthly amount glided 48.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, The Benchmark Company downgraded its rating to Hold on August 20, 2024. On February 22, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $6 on December 05, 2023. The Benchmark Company downgraded its rating to a Hold. In a note dated February 28, 2023, Cowen initiated an Outperform rating.
For the past year, the stock price of AbCellera Biologics Inc fluctuated between $1.89 and $4.70. Currently, Wall Street analysts expect the stock to reach $20.17 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $5.15 at the most recent close of the market. An investor can expect a potential return of 291.65% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
According to AbCellera Biologics Inc [NASDAQ:ABCL], the company’s sales were 23.12M for trailing twelve months, which represents an -57.45% plunge. Gross Profit Margin for this corporation currently stands at -4.74% with Operating Profit Margin at -15.79%, Pretax Profit Margin comes in at -9.11%, and Net Profit Margin reading is -7.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.16 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that AbCellera Biologics Inc [NASDAQ:ABCL] has a current ratio of 10.15. Also, the Quick Ratio is 10.15, while the Cash Ratio stands at 2.11. Considering the valuation of this stock, the price to sales ratio is 66.49, the price to book ratio is 1.50.
